Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial -

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Cancers | Endocrine system disorders
Summary
Ribociclib plus endocrine therapy improved progression-free survival vs placebo plus endocrine therapy (n=627; median progression-free survival 23.8 vs 13.0 months ; HR 0.55, 95% CI 0.44–0.69; p<0.0001).
UKMi comment
An accompanying editorial discusses the findings of this study in relation to their potential place in therapy.
Related links: Comment